Glucagon cell hyperplasia and neoplasia with and without glucagon receptor mutations

Bence Sipos, Jan Sperveslage, Martin Anlauf, Maike Hoffmeister, Tobias Henopp, Stephan Buch, Jochen Hampe, Achim Weber, Pascal Hammel, Anne Couvelard, Walter Höbling, Wolfgang Lieb, Bernhard O. Boehm, Günter Klöppel

Research output: Contribution to journalArticlepeer-review

51 Scopus citations

Abstract

Context: Glucagon cell adenomatosis (GCA) was recently recognized as a multifocal hyperplastic and neoplastic disease of the glucagon cells unrelated to multiple endocrine neoplasia type 1 and von-Hippel-Lindau disease. Objective: The study focused on the molecular analysis of the glucagon receptor (GCGR) gene in GCA and a description of the clinicopathological features of GCA with and without GCGR mutations. Design: Pancreatic tissues from patients showing multiple glucagon cell tumors were morphologically characterized and macro- or microdissected. All exons of the GCGR gene were analyzed for mutations by Sanger and next-generation sequencing. Genotyping for all detected GCGR variants was performed in 2560 healthy individuals. Patients: Six patients with GCA, and the parents of one patient were included in the study. Main Outcome Measures: The main outcome measures were the correlations between the patients' GCGR mutation status and the respective clinicopathological data. Results: GCGR germline mutations were found in three of six patients. Patient 1 harbored a homozygous stop mutation. This patient's parents showed an identical but heterozygous GCGR mutation. Patient 2 had two different heterozygous point mutations leading each to premature stop codons. Patient 3 exhibited two homozygous missense mutations. No GCGR mutations were identified in the three other patients and in a large cohort of healthy subjects. The patients harboring GCGR mutations exhibited a greater number of tumors and larger tumors than patients with wild-type GCGR. One of the patients with wild-type GCGR showed lymph node micrometastases. Conclusions: GCA with GCGR germline mutations seems to follow an autosomal-recessive trait. By interrupting the GCGR signaling pathways GCGR mutations probably cause GCA via glucagon cell hyperplasia. GCA also occurs in patients without GCGR mutations, but seems to be associated with fewer and smaller tumors.

Original languageEnglish
Pages (from-to)E783-E788
JournalJournal of Clinical Endocrinology and Metabolism
Volume100
Issue number5
DOIs
StatePublished - 1 May 2015

Fingerprint

Dive into the research topics of 'Glucagon cell hyperplasia and neoplasia with and without glucagon receptor mutations'. Together they form a unique fingerprint.

Cite this